Genentech, Inc.

Medshine Discovery Inc.

Constellation Pharmaceuticals, Inc.

Harbin Zhenbao Pharmaceutical Co., Ltd.

F. Hoffmann-la Roche Ag

Jiangpeng Liao

Jun Liang

Nicholas Charles Ray

Xiaojing Wang

Daniel Fred Ortwine

Sharada Shenvi Labadie

Birong Zhang

Simon Charles Goodacre

Jun M Li

Jason R Zbieg

Shuhui Chen

Jian Li

Tao Wang

Bing-Yan Zhu

Fei Wang

Peng Li

Brian K Albrecht

Steven R Magnuson

F Anthony Romero

Fei Sun

Guoping Hu

Kevin X Chen

Alexander M Taylor

Vickie Hsiao-Wei Tsui

Richard Pastor

Zhengxia Chen

Kwong Wah Lai

Terry Crawford

Alexandre Cote

Cheng Xie

Meibi Dai

Alexandre Côté

Steven Elliot Kauder

Zhiguo Liu

Sarah Bronner

Guibai Liang

John Wai

Jeremy M Murray

Patrick Cyr

Tommy Lai

Jackson G Egen

Marc Adler

Jackson Egen

Jason Zbieg

Jun Li

Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure:  and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof

Described herein are heteroaryl compounds with estrogen receptor modulation activity or function having the Formula I, II, and III structures: and

Heteroaryl estrogen receptor modulators and uses thereof

FGFR and VEGFR inhibitors are provided, and compounds represented by formula (1) or formula (II) as FGFR and VEGFR inhibitors, pharmaceutically acceptable salts or tautomers thereof are specifically disclosed.

Vinyl compounds as FGFR and VEGFR inhibitors

The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R-Rof formula (I) and R-Rof formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

Therapeutic compounds and uses thereof

Growing community of inventors

Shanghai, China

Jiangpeng Liao